- Home
- NML vs AUTL Comparison
NML vs AUTL Comparison
Compare NML & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.47
Company Overview
Basic Information| Metric | NML | AUTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.5M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | NML | AUTL |
|---|---|---|
| Price | $10.34 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 191.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $84.74 |
| Revenue Next Year | N/A | $65.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $7.70 | $1.11 |
| 52 Week High | $10.71 | $2.70 |
Technical Indicators
Market Signals| Indicator | NML | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 52.74 |
| Support Level | $8.38 | $1.45 |
| Resistance Level | $10.44 | $1.52 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 62.67 | 90.77 |
Price Performance
Historical Comparison NML
AUTL
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.